1John D. Mc Connell. Epidemiology, etiology pathophysiology and diagnosis of benign prostatic hyperplasia. Campbell' s Urology. seventh edition. USA: Saundors Co, 1992:1431
2Lepor H, Auerbach S, Puras-baez A, et al. A randomized,placebocontrolled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia.J Urol 1992; 148:1467
3Breza J, Dzumy O, Borowka A, et al. Efficacy and acceptability of tadenan(Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe. Curr Med Res Opin 1998;14(3):127
5Yablonsky F, Nicolas V, Riffaud JP, et al. Antiproliferativeeffect of Pygeum africanum extract on rat prostatic fibroblasts. J Urol 1997; 157(6) :2381
6Paubert-braquet M, Monboisse JC, Sexvent-Saez N, et al. Inhibition of bFGF and EGF-induced proliferation of 3T3 fibroblasts by extract of Pygeum africanum (Tadenan).Biomed Pharmacother 1994;48(Suppl 1) :43
7Chatelain C,Autet W,Brackman F. Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension. Urology 1999;54(3) :473
8Story MT. Positive and negative modulators of prostate cell proliferation. Biomad Pharmacother 1994;48(Suppl 1) :35
9CAINE M, RAZ S,ZEIGLER M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck[J]. Br J Urol,1975,47(2) :193-202.
10NARAYAN P,EVANS C P,MOON T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia [ J ]. J Urol,2003,170 ( 2Pt1) :498-502.
